Stock of the Day

Genmab A/S (GMAB)

$37.82

+$0.93 (+2.5%)

Market Cap: $23.02B

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.

Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.

Genmab A/S Bull Case

Here are some ways that investors could benefit from investing in Genmab A/S:

• Genmab A/S recently announced positive topline results from the Phase 3 EPCORE DLBCL-2 trial, demonstrating that epcoritamab in combination with R-CHOP significantly improved progression-free survival in newly diagnosed diffuse large B-cell lymphoma patients, a key growth driver for the company's pipeline.
• Analyst sentiment has turned strongly positive, with HC Wainwright raising its price target to $50.00 and Truist Financial lifting its target to $45.00, both maintaining Buy ratings, which suggests significant upside potential from the current stock price of $36.05.
• The company demonstrated strong financial performance in its most recent quarterly report, beating consensus estimates with earnings per share of $0.54 compared to the expected $0.37, and achieving revenue of $1.16 billion against expectations of $1.12 billion.
• Short interest in Genmab A/S has decreased significantly over the past several months, dropping from over 11 million shares shorted in late 2025 to approximately 4.9 million shares as of September 2026, indicating that investors are increasingly confident in the stock's direction.
• Genmab A/S continues to expand its market presence through strategic collaborations, including a recent announcement of a 45.9% response rate for Rina-S in an ovarian cancer trial, further validating its antibody-based medicine platform.

Genmab A/S Bear Case

Investors should be bearish about investing in Genmab A/S for these reasons:

• The stock is currently trading at a price-to-earnings ratio of 26.37, which is relatively high compared to the broader market, suggesting that the stock may be overvalued if future earnings growth does not meet the elevated expectations set by recent trial successes.
• Despite recent positive news, the stock price has experienced volatility, including a gap down of 1.38% on January 28, 2026, and a decline of 1.6% in recent trading, indicating that the market may be skeptical about the sustainability of the recent price gains.
• Genmab A/S has a beta of 0.81, which is lower than the market average, but the stock has still experienced significant price swings, such as a 10.7% jump in a single session, which could lead to unpredictable short-term movements for investors.
• The company's debt-to-equity ratio is 0.81, which, while manageable, indicates a moderate level of leverage that could become a concern if interest rates rise or if the company faces unexpected financial challenges.
• While the consensus rating is Moderate Buy, there are still three analysts who have issued a Hold rating, suggesting that some investors believe the stock is fairly valued and may not have significant upside potential in the near term.

Recent News

• Barclays Sticks to Their Buy Rating for Genmab A/S (0MGB) (theglobeandmail.com)
• Genmab Reports $4.24 Billion In Third-Quarter DARZELEX Sales, Up Year Over Year (rttnews.com)
• Genmab Reports $4.24 Billion in Q3 DARZALEX Sales, Earns Royalties From J&J (finance.yahoo.com)
• Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2026 (globenewswire.com)